vs
ICU MEDICAL INC（ICUI）与MONRO, INC.（MNRO）财务数据对比。点击上方公司名可切换其他公司
ICU MEDICAL INC的季度营收约是MONRO, INC.的1.8倍（$540.7M vs $293.4M），MONRO, INC.净利率更高（3.8% vs -2.9%，领先6.7%），MONRO, INC.同比增速更快（-4.0% vs -14.1%），ICU MEDICAL INC自由现金流更多（$36.0M vs $9.1M），过去两年ICU MEDICAL INC的营收复合增速更高（-2.3% vs -2.7%）
ICU医疗是总部位于美国加利福尼亚州圣克莱门特的医疗科技企业，专注于研发预防血流感染、保护医护人员免受传染病或危险药物侵害的医疗产品，产品线覆盖静脉治疗用品、输液泵、无针血管通路设备、定制输液套装、危险药物密闭处理系统、传感导管以及无针封闭式血液采样系统等。
蒙罗公司（Monro, Inc.）是一家汽车服务企业，创始并总部设在美国纽约州罗切斯特。截至2025年，蒙罗共拥有1260家门店，按门店数量与营收计算，是北美仅次于Driven Brands的第二大汽车服务企业。
ICUI vs MNRO — 直观对比
营收规模更大
ICUI
是对方的1.8倍
$293.4M
营收增速更快
MNRO
高出10.1%
-14.1%
净利率更高
MNRO
高出6.7%
-2.9%
自由现金流更多
ICUI
多$26.8M
$9.1M
两年增速更快
ICUI
近两年复合增速
-2.7%
损益表 — Q4 FY2025 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $540.7M | $293.4M |
| 净利润 | $-15.7M | $11.1M |
| 毛利率 | 37.5% | 34.9% |
| 营业利润率 | 1.0% | 6.3% |
| 净利率 | -2.9% | 3.8% |
| 营收同比 | -14.1% | -4.0% |
| 净利润同比 | 34.0% | 143.1% |
| 每股收益（稀释后） | $-0.63 | $0.35 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ICUIMNRO
| Q4 25 | $540.7M | $293.4M | ||
| Q3 25 | $537.0M | $288.9M | ||
| Q2 25 | $548.9M | $301.0M | ||
| Q1 25 | $604.7M | $295.0M | ||
| Q4 24 | $629.8M | $305.8M | ||
| Q3 24 | $589.1M | $301.4M | ||
| Q2 24 | $596.5M | $293.2M | ||
| Q1 24 | $566.7M | $310.1M |
净利润ICUIMNRO
| Q4 25 | $-15.7M | $11.1M | ||
| Q3 25 | $-3.4M | $5.7M | ||
| Q2 25 | $35.3M | $-8.1M | ||
| Q1 25 | $-15.5M | $-21.3M | ||
| Q4 24 | $-23.8M | $4.6M | ||
| Q3 24 | $-33.0M | $5.6M | ||
| Q2 24 | $-21.4M | $5.9M | ||
| Q1 24 | $-39.5M | $3.7M |
毛利率ICUIMNRO
| Q4 25 | 37.5% | 34.9% | ||
| Q3 25 | 37.4% | 35.7% | ||
| Q2 25 | 37.9% | 35.5% | ||
| Q1 25 | 34.7% | 33.0% | ||
| Q4 24 | 36.1% | 34.3% | ||
| Q3 24 | 34.8% | 35.3% | ||
| Q2 24 | 34.8% | 37.2% | ||
| Q1 24 | 32.7% | 35.5% |
营业利润率ICUIMNRO
| Q4 25 | 1.0% | 6.3% | ||
| Q3 25 | 2.6% | 4.4% | ||
| Q2 25 | 1.9% | -2.0% | ||
| Q1 25 | 2.1% | -8.1% | ||
| Q4 24 | 6.0% | 3.3% | ||
| Q3 24 | 1.4% | 4.4% | ||
| Q2 24 | 1.3% | 4.5% | ||
| Q1 24 | -1.9% | 3.3% |
净利率ICUIMNRO
| Q4 25 | -2.9% | 3.8% | ||
| Q3 25 | -0.6% | 2.0% | ||
| Q2 25 | 6.4% | -2.7% | ||
| Q1 25 | -2.6% | -7.2% | ||
| Q4 24 | -3.8% | 1.5% | ||
| Q3 24 | -5.6% | 1.9% | ||
| Q2 24 | -3.6% | 2.0% | ||
| Q1 24 | -7.0% | 1.2% |
每股收益（稀释后）ICUIMNRO
| Q4 25 | $-0.63 | $0.35 | ||
| Q3 25 | $-0.14 | $0.18 | ||
| Q2 25 | $1.43 | $-0.28 | ||
| Q1 25 | $-0.63 | $-0.74 | ||
| Q4 24 | $-0.97 | $0.15 | ||
| Q3 24 | $-1.35 | $0.18 | ||
| Q2 24 | $-0.88 | $0.19 | ||
| Q1 24 | $-1.63 | $0.12 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $4.9M |
| 总债务越低越好 | — | $45.0M |
| 股东权益账面价值 | $2.1B | $604.9M |
| 总资产 | $4.1B | $1.6B |
| 负债/权益比越低杠杆越低 | — | 0.07× |
8季度趋势，按日历期对齐
现金及短期投资ICUIMNRO
| Q4 25 | — | $4.9M | ||
| Q3 25 | — | $10.5M | ||
| Q2 25 | — | $7.8M | ||
| Q1 25 | — | $20.8M | ||
| Q4 24 | $308.6M | $10.2M | ||
| Q3 24 | $312.5M | $20.9M | ||
| Q2 24 | $302.6M | $18.7M | ||
| Q1 24 | $251.4M | $6.6M |
总债务ICUIMNRO
| Q4 25 | — | $45.0M | ||
| Q3 25 | — | $60.0M | ||
| Q2 25 | — | $71.5M | ||
| Q1 25 | — | $61.3M | ||
| Q4 24 | — | $59.3M | ||
| Q3 24 | — | $62.0M | ||
| Q2 24 | — | $112.0M | ||
| Q1 24 | — | $102.0M |
股东权益ICUIMNRO
| Q4 25 | $2.1B | $604.9M | ||
| Q3 25 | $2.1B | $601.7M | ||
| Q2 25 | $2.1B | $604.9M | ||
| Q1 25 | $2.0B | $620.8M | ||
| Q4 24 | $2.0B | $648.9M | ||
| Q3 24 | $2.0B | $651.9M | ||
| Q2 24 | $2.0B | $654.4M | ||
| Q1 24 | $2.1B | $656.8M |
总资产ICUIMNRO
| Q4 25 | $4.1B | $1.6B | ||
| Q3 25 | $4.1B | $1.6B | ||
| Q2 25 | $4.1B | $1.6B | ||
| Q1 25 | $4.2B | $1.6B | ||
| Q4 24 | $4.2B | $1.7B | ||
| Q3 24 | $4.3B | $1.7B | ||
| Q2 24 | $4.3B | $1.7B | ||
| Q1 24 | $4.3B | $1.7B |
负债/权益比ICUIMNRO
| Q4 25 | — | 0.07× | ||
| Q3 25 | — | 0.10× | ||
| Q2 25 | — | 0.12× | ||
| Q1 25 | — | 0.10× | ||
| Q4 24 | — | 0.09× | ||
| Q3 24 | — | 0.10× | ||
| Q2 24 | — | 0.17× | ||
| Q1 24 | — | 0.16× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $60.6M | $17.8M |
| 自由现金流经营现金流 - 资本支出 | $36.0M | $9.1M |
| 自由现金流率自由现金流/营收 | 6.6% | 3.1% |
| 资本支出强度资本支出/营收 | 4.6% | 3.0% |
| 现金转化率经营现金流/净利润 | — | 1.60× |
| 过去12个月自由现金流最近4个季度 | $91.8M | $49.6M |
8季度趋势，按日历期对齐
经营现金流ICUIMNRO
| Q4 25 | $60.6M | $17.8M | ||
| Q3 25 | $56.7M | $32.3M | ||
| Q2 25 | $11.2M | $-1.9M | ||
| Q1 25 | $51.3M | $28.9M | ||
| Q4 24 | $40.2M | $14.8M | ||
| Q3 24 | $36.1M | $62.6M | ||
| Q2 24 | $82.0M | $25.6M | ||
| Q1 24 | $45.8M | $-5.3M |
自由现金流ICUIMNRO
| Q4 25 | $36.0M | $9.1M | ||
| Q3 25 | $27.6M | $26.6M | ||
| Q2 25 | $-8.5M | $-9.3M | ||
| Q1 25 | $36.7M | $23.2M | ||
| Q4 24 | $16.1M | $7.9M | ||
| Q3 24 | $16.2M | $57.6M | ||
| Q2 24 | $62.5M | $16.8M | ||
| Q1 24 | $29.9M | $-11.9M |
自由现金流率ICUIMNRO
| Q4 25 | 6.6% | 3.1% | ||
| Q3 25 | 5.1% | 9.2% | ||
| Q2 25 | -1.5% | -3.1% | ||
| Q1 25 | 6.1% | 7.9% | ||
| Q4 24 | 2.6% | 2.6% | ||
| Q3 24 | 2.7% | 19.1% | ||
| Q2 24 | 10.5% | 5.7% | ||
| Q1 24 | 5.3% | -3.8% |
资本支出强度ICUIMNRO
| Q4 25 | 4.6% | 3.0% | ||
| Q3 25 | 5.4% | 2.0% | ||
| Q2 25 | 3.6% | 2.5% | ||
| Q1 25 | 2.4% | 1.9% | ||
| Q4 24 | 3.8% | 2.2% | ||
| Q3 24 | 3.4% | 1.6% | ||
| Q2 24 | 3.3% | 3.0% | ||
| Q1 24 | 2.8% | 2.1% |
现金转化率ICUIMNRO
| Q4 25 | — | 1.60× | ||
| Q3 25 | — | 5.71× | ||
| Q2 25 | 0.32× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 3.23× | ||
| Q3 24 | — | 11.08× | ||
| Q2 24 | — | 4.37× | ||
| Q1 24 | — | -1.42× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ICUI
| Infusion Consumables | $284.7M | 53% |
| Infusion Systems | $176.3M | 33% |
| Vital Care | $79.7M | 15% |
MNRO
| Tires | $150.2M | 51% |
| Maintenance | $73.5M | 25% |
| Brakes | $35.1M | 12% |
| Steering | $24.9M | 8% |
| Batteries | $6.2M | 2% |
| Exhaust | $3.2M | 1% |
